VACC
VACCITECH PLC
$2.24
Earnings Summary
Revenue | $0.04Mn |
Net Profits | $-15.93Mn |
Net Profit Margins | -45505.71% |
Highlights
VACCITECH PLC’s revenue fell -93.15% since last year same period to $0.04Mn in the Q2 2021. On a quarterly growth basis, VACCITECH PLC has generated -83.72% fall in its revenue since last 3-months.
VACCITECH PLC’s net profit fell -343.9% since last year same period to $-15.93Mn in the Q2 2021. On a quarterly growth basis, VACCITECH PLC has generated -4.32% fall in its net profits since last 3-months.
VACCITECH PLC’s net profit margin fell -6380.89% since last year same period to -45505.71% in the Q2 2021. On a quarterly growth basis, VACCITECH PLC has generated -540.8% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the VACCITECH PLC post its latest quarter earnings
EPS Estimate Current Quarter | -0.55 |
EPS Estimate Current Year | -0.55 |
Highlights
VACCITECH PLC’s earning per share (EPS) estimates for the current quarter stand at -0.55 - a -81.82% fall from last quarter’s estimates.
VACCITECH PLC’s earning per share (EPS) estimates for the current year stand at -0.55.
Key Ratios
Key ratios of the VACCITECH PLC post its Q1 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
VACCITECH PLC’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2023. This indicates that the VACCITECH PLC has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2021-06-14 | -2.11 | -1.9 | 9.95% |
2022-03-25 | -0.51 | -0.38 | 25.49% |
2021-11-12 | -0.45 | -0.13 | 71.11% |
2021-08-12 | -0.74 | -0.64 | 13.51% |
Company Information
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.
Organisation | VACCITECH PLC |
Headquarters | The SchrOedinger Building, Oxford, United Kingdom, OX4 4GE |
Employees | 33 |
Industry | Healthcare |
